JP7844766B2 - 抗特発性肺線維症薬ニンテダニブの結核を治療するための使用 - Google Patents

抗特発性肺線維症薬ニンテダニブの結核を治療するための使用

Info

Publication number
JP7844766B2
JP7844766B2 JP2024553621A JP2024553621A JP7844766B2 JP 7844766 B2 JP7844766 B2 JP 7844766B2 JP 2024553621 A JP2024553621 A JP 2024553621A JP 2024553621 A JP2024553621 A JP 2024553621A JP 7844766 B2 JP7844766 B2 JP 7844766B2
Authority
JP
Japan
Prior art keywords
tuberculosis
treatment
nintedanib
drug
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024553621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508098A5 (cg-RX-API-DMAC10.html
JP2025508098A (ja
Inventor
宇 陸
効友 陳
雪▲テイ▼ 祁
▲ロ▼瑶 鄭
雷 付
▲イ▼▲エン▼ 張
寧 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Chest Hospital
Original Assignee
Beijing Chest Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Chest Hospital filed Critical Beijing Chest Hospital
Publication of JP2025508098A publication Critical patent/JP2025508098A/ja
Publication of JP2025508098A5 publication Critical patent/JP2025508098A5/ja
Application granted granted Critical
Publication of JP7844766B2 publication Critical patent/JP7844766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024553621A 2022-04-29 2023-03-16 抗特発性肺線維症薬ニンテダニブの結核を治療するための使用 Active JP7844766B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210463752.6A CN114732818B (zh) 2022-04-29 2022-04-29 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用
CN202210463752.6 2022-04-29
PCT/CN2023/081772 WO2023207398A1 (zh) 2022-04-29 2023-03-16 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用

Publications (3)

Publication Number Publication Date
JP2025508098A JP2025508098A (ja) 2025-03-21
JP2025508098A5 JP2025508098A5 (cg-RX-API-DMAC10.html) 2025-06-16
JP7844766B2 true JP7844766B2 (ja) 2026-04-14

Family

ID=82285173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553621A Active JP7844766B2 (ja) 2022-04-29 2023-03-16 抗特発性肺線維症薬ニンテダニブの結核を治療するための使用

Country Status (5)

Country Link
US (1) US20250099458A1 (cg-RX-API-DMAC10.html)
JP (1) JP7844766B2 (cg-RX-API-DMAC10.html)
CN (1) CN114732818B (cg-RX-API-DMAC10.html)
WO (1) WO2023207398A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202405173B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732818B (zh) * 2022-04-29 2023-02-10 首都医科大学附属北京胸科医院 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用
CN115645405B (zh) * 2022-11-10 2023-11-21 南方医科大学 顺苯磺酸阿曲库铵在制备抗结核抗生素增效剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105902507A (zh) 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种乙磺酸尼达尼布制剂及其应用
CN107019697A (zh) 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857725A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种含增效剂的复方抗结核药物缓释制剂
EP2311457A1 (en) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
WO2015107482A1 (en) * 2014-01-17 2015-07-23 Piramal Enterprises Limited Pharmaceutical combination for treatment of tuberculosis
ES2738678T3 (es) * 2016-01-08 2020-01-24 Nerre Therapeutics Ltd Orvepitant para el tratamiento de la tos crónica
GB201607865D0 (en) * 2016-05-05 2016-06-22 Ucl Business Plc Anti-tuberculous polymersomes
CN114732818B (zh) * 2022-04-29 2023-02-10 首都医科大学附属北京胸科医院 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107019697A (zh) 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
CN105902507A (zh) 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种乙磺酸尼达尼布制剂及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Molecules，2019年11月29日，Vol. 24, No. 23，p.4373，DOI:10.3390/molecules24234373
日本結核病学会治療委員会，「結核医療の基準」の改定－２０１８年 ，結核，2018年，Vol.93,No.1，p.61-68

Also Published As

Publication number Publication date
CN114732818A (zh) 2022-07-12
ZA202405173B (en) 2024-07-31
WO2023207398A1 (zh) 2023-11-02
JP2025508098A (ja) 2025-03-21
US20250099458A1 (en) 2025-03-27
CN114732818B (zh) 2023-02-10

Similar Documents

Publication Publication Date Title
AU2022407131C1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2025508098A (ja) 抗特発性肺線維症薬ニンテダニブの結核を治療するための使用
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
JP2024541514A (ja) 進行性線維化を伴う間質性肺疾患を処置するための、新たな治療的組合せ
CN117045657A (zh) 一种药物组合及其应用
WO2019033122A1 (en) TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
KR20020075797A (ko) 엔도텔린 유발성 질환 치료제
EP3320901B1 (en) Dimethylaminomicheliolide for use in the treatment of pulmonary fibrosis
US20230149393A1 (en) Inhibitors of trpc6 for treating respiratory conditions
US20200354336A9 (en) Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
JP2025533322A (ja) （－）－エピガロカテキンガレート化合物の使用
JP7433331B2 (ja) 特発性肺線維症を治療するための組成物及び方法
CN117398372A (zh) Ostarine在抑制NLRP3炎症小体活化中的应用
WO2011109472A1 (en) Compositions comprising myristic acid and uses thereof
JP2022539583A (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
CN115778936A (zh) 松萝酸协同增效多黏菌素在抗革兰氏阴性细菌感染中的应用
EP2036562A1 (en) A1 adenosine receptor antagonist for preventing and treating tissue injury and sepsis associated with yersinia pestis infection
CN114366730B (zh) 没食子酸及包含其的药物组合物用于治疗细菌性前列腺炎的应用
WO2026098636A1 (zh) Pde4抑制剂用于治疗和/或预防肺部疾病的用途
CN119139378A (zh) 神香草挥发油及包含其的组合物在制备治疗特发性肺纤维化药物中的应用
CN120379693A (zh) 一种药物组合及应用
CN118369098A (zh) 用于治疗进行性纤维化间质性肺病的新颖治疗组合
CN119367370A (zh) 用于治疗肺癌的联合药物
CN121265594A (zh) 治疗急性心肌梗死的药物组合物、制剂及用途
TW201725037A (zh) 亞丁基苯酞之應用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260210

R150 Certificate of patent or registration of utility model

Ref document number: 7844766

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150